Stock Yearly Return 2018
Start date: 01/02/2018
End date: 12/31/2018
Start price/share: $33.60
End price/share: $11.48
Dividends collected/share: $0.00
Total return: -65.83%
MRNS Average Annual Return: -66.20%
Starting investment: $10,000.00
Ending investment: $3,417.00
Years: 0.99


MRNS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare MRNS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into MRNS


Also see:
MRNS stock yearly return 2019
MRNS stock yearly return 2020
MRNS YTD return
MRNS average annual return 10 years
Marinus Pharmaceuticals is a clinical stage pharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare seizure disorders. Co.'s clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA that is being developed in formulations for two different routes of administration: intravenous and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. The different formulations are intended to improve potential therapeutic applications of ganaxolone for adult and pediatric patient populations, in both acute and chronic care, and for both in-patient and self-administered settings. The MRNS stock yearly return is shown above.

The yearly return on the MRNS stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2018 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the MRNS annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for MRNS:
MRNS SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Marinus Pharmaceuticals (MRNS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

MRSN Average Annual Return
MRTX Average Annual Return
MSON Average Annual Return
MTEM Average Annual Return
MYGN Average Annual Return
MYL Average Annual Return
MYND Average Annual Return
MYOK Average Annual Return
NAOV Average Annual Return
NBIX Average Annual Return
More Healthcare companies »

 

MRNS Stock Yearly Return 2018 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.